Robin Rudd
Overview
Explore the profile of Robin Rudd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee S, Hewish M, Ahmed S, Papadatos-Pastos D, Karapanagiotou E, Blackhall F, et al.
Eur J Cancer
. 2024 Dec;
215:115162.
PMID: 39693892
Background: Most patients with small-cell lung cancer (SCLC) present with extensive-stage (ES) disease and have a poor prognosis despite achieving high initial response rates to platinum-based doublet chemotherapy. This study...
2.
Lee S, Upadhyay S, Lewanski C, Falk S, Skailes G, Woll P, et al.
Eur J Cancer
. 2019 Sep;
120:86-96.
PMID: 31499384
Purpose: We previously demonstrated that the median survival of patients with poor prognosis non-small cell lung cancer (NSCLC) considered unfit for first-line platinum chemotherapy was <4 months. We evaluated whether...
3.
Lee S, Falzon M, Blackhall F, Spicer J, Nicolson M, Chaudhuri A, et al.
J Clin Oncol
. 2016 Nov;
35(4):402-411.
PMID: 27893326
Purpose Retrospective studies indicate that expression of excision repair cross complementing group 1 (ERCC1) protein is associated with platinum resistance and survival in non-small-cell lung cancer (NSCLC). We conducted the...
4.
Lee S, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, et al.
Lancet Oncol
. 2012 Oct;
13(11):1161-70.
PMID: 23078958
Background: Many patients with advanced non-small-cell lung cancer (NSCLC) receive only active supportive care because of poor performance status or presence of several comorbidities. We investigated whether erlotinib improves clinical...
5.
Blayney J, Ceresoli G, Castagneto B, OBrien M, Hasan B, Sylvester R, et al.
Eur J Cancer
. 2012 Jun;
48(16):2983-92.
PMID: 22704893
Background: There is currently no early predictive marker of survival for patients receiving chemotherapy for malignant pleural mesothelioma (MPM). Tumour response may be predictive for overall survival (OS), though this...
6.
Lee S, Rudd R, Woll P, Ottensmeier C, Gilligan D, Price A, et al.
J Clin Oncol
. 2009 Sep;
27(31):5248-54.
PMID: 19770378
Purpose: Cancers rely on angiogenesis for their growth and dissemination. We hypothesized that thalidomide, an oral antiangiogenic agent, when combined with chemotherapy, and as maintenance treatment, would improve survival in...
7.
Lee S, Woll P, Rudd R, Ferry D, OBrien M, Middleton G, et al.
J Natl Cancer Inst
. 2009 Jul;
101(15):1049-57.
PMID: 19608997
Background: Cancer cells rely on angiogenesis for growth and dissemination, and small cell lung cancer (SCLC) is a highly angiogenic tumor. We evaluated thalidomide, an anti-angiogenic agent, when combined with...
8.
Muers M, Stephens R, Fisher P, Darlison L, Higgs C, Lowry E, et al.
Lancet
. 2008 May;
371(9625):1685-94.
PMID: 18486741
Background: Malignant pleural mesothelioma is almost always fatal, and few treatment options are available. Although active symptom control (ASC) has been recommended for the management of this disease, no consensus...
9.
Saha A, Rudd R
Expert Rev Anticancer Ther
. 2006 Feb;
6(2):165-73.
PMID: 16445369
Approximately 30-40% of non-small cell lung cancer patients will present with metastatic disease, and its associated poor prognosis. Chemotherapy has an established palliative role within late-stage disease, but is also...
10.
Fairlamb D, Milroy R, Gower N, Parmar M, Peake M, Rudd R, et al.
Radiother Oncol
. 2005 Aug;
75(2):134-140.
PMID: 16094738
Background: A meta-analysis of trials comparing primary treatment with or without chemotherapy for patients with non-small cell lung cancer published in 1995 suggested a survival benefit for cisplatin-based chemotherapy in...